Trump rolls out pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk. Analysts say the pact raises more questions than it answers.

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare and Medicaid beneficiaries and to users of TrumpRx.

Certain obesity drugs will cost as little as $149 and Medicare will start covering them under White House deals

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have access to them under two deals announced Thursday by the Trump administration.
ConsumerAffairs

Medicare negotiates new prices for Ozempic and Wegovy

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) to set a negotiated price for

Novo Nordisk Stock Rises After Earnings. It Cut Guidance on These Fears.

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.
Feedback